Shanghai Bangyao Biotechnology Co., Ltd. is committed to becoming the world's leading cell gene pharmaceutical company in the era of new commercial civilization. With the mission of "leading innovation with gene editing, developing breakthrough therapies and benefiting all mankind", Bangyao Biotechnology has produced more than 65,438+000 patent achievements in the past five years, and five projects have carried out clinical trials initiated by researchers in eight well-known hospitals.

Among them, gene editing for β -thalassemia, non-viral PD 1 fixed-point integration CAR-T, UCART and other projects have achieved excellent clinical results, leading the world, and published many academic papers in well-known academic journals such as Nature, NatureMedicine and Naturebiotechnology. Bangyao Bio has built five technical platforms with independent intellectual property rights: gene editing technology innovation platform, hematopoietic stem cell platform, non-virus fixed-point integration CAR-T platform, universal cell platform and enhanced T cell platform. It has a GMP pilot base of 7,000 square meters and an operation team of nearly 200 people, effectively ensuring the rapid transformation and application of innovative research results.

Bangyao Bio constantly promotes the rapid update iteration of R&D products through patient needs and clinical feedback. And uphold the attitude of openness, * * enjoyment and * * * win, and work with global innovative biomedical eco-chain enterprises to accelerate the transformation and landing of innovative drugs for the benefit of patients with genetic diseases and malignant tumors around the world!